Sustainability at Biocon

Biosimilars Q4FY22 and full year FY22 Revenue Core EBITDA % margin Q4 FY22 Q4 FY21 *982Cr Biocon Biologics | FY22 FY 21 *664Cr +48% *3,464Cr *2,800Cr +24% * *382Cr *215Cr +78% *1,320Cr *1,010Cr+30% 39% 33% 39% 36% Profit Before Tax *144Cr *69Cr +109% *543Cr *365Cr +49% before Exceptional Items % margin 15% 10% 16% 13% *Core EBITDA defined as EBITDA before R&D, forex, licensing and mark-to-market loss on investments 22 22

View entire presentation